|
|
|
|||||||
|
|||||||||
J Biol Chem, Vol. 273, Issue 49, 32771-32775, December 4, 1998
From the Splicing of pre-mRNAs involves two sequential
transesterification reactions commonly referred to as the first and
second steps. In Saccharomyces cerevisiae, four proteins,
Prp16p, Prp17p, Prp18p, and Slu7p are exclusively required for the
second step of splicing. The human homologs of Prp16p, Prp17p, and
Prp18p have been identified, and the human proteins hPrp16 and hPrp18
have been shown to be required for the second step of splicing in
vitro. Here we provide further evidence for the functional
conservation of the second step factors between yeast and humans. Human
hPrp17, which is 35% identical to the S. cerevisiae
protein, is able to partially rescue the temperature-sensitive
phenotype in a yeast strain where PRP17 has been knocked
out, suggesting that the human and yeast proteins are functionally
conserved. Overexpression of hPrp17 in the knockout yeast strain
partially rescues the splicing defect seen in vitro and
in vivo. In HeLa cells, hPrp17 is highly concentrated in
the nuclear speckles, as is SC35 and many other splicing factors, thus
providing further support that this protein also functions as a
splicing factor in humans.
Splicing is the process by which introns are removed from
pre-mRNAs, and it occurs via two phosphoryl transfer reactions
(reviewed in Ref. 1). In the first step, the 5'-exon is cleaved
concomitantly with the production of a lariat intermediate. In the
second step, the 3'-splice site is cleaved, the exons are ligated, and
the intron is released as a lariat product. This process is catalyzed by a multi-component enzyme called the spliceosome. The conventional sliceosome is formed on the pre-mRNA by the assembly of U1, U2, U4/U6, and U5 snRNPs,1 as
well as a large number of non-snRNP splicing factors.
Genetic screens in Saccharomyces cerevisiae have lead to the
identification of four proteins (Prp16p, Prp17p, Prp18p, and Slu7p)
that are specifically required for the second step of splicing in yeast
(reviewed in Ref. 2). Mutations in PRP16, PRP17,
and PRP18 cause accumulation of splicing reaction
intermediates at nonpermissive temperature (3, 4). The genes that
encode Prp17p and Prp18p are not essential for cell survival, and
absence of either protein causes only a partial block to the second
step of splicing in vitro (5, 6). This may be because of
overlapping functions in some of the second step splicing factors. In
fact, the overexpression of Prp16p can suppress a PRP17
mutation, and overexpression of Slu7p suppresses a PRP18
mutation (6).
Mutations in SLU7 (slu7-1) and
PRP17 (slu4-1) are synthetically
lethal with mutations in the invariant loop 1 of U5 snRNA (7). U5 snRNA
interacts with exon sequences at both the 5'- and 3'-splice sites and
most likely plays a significant role in aligning the two exons during
the second step of splicing (reviewed in Ref. 1). Prp8p, a highly
conserved U5 snRNP protein, is required for specificity and fidelity of
3'-splice site utilization (8, 9). Alleles of PRP16, PRP17,
PRP18, and SLU7 are all synthetically lethal with an
allele of PRP8, prp8-101, which impairs recognition of the 3'-splice site and inhibits the second step (8).
These and other genetic studies indicate that there may be a network of
physical interactions between Prp16p, Prp17p, Prp18p, Slu7p, and Prp8p
(reviewed in Ref. 2).
The requirements for Prp16p, Prp17p, Prp18p, and Slu7p have been
temporally ordered with respect to each other and to the requirement
for ATP hydrolysis during the second step of splicing (reviewed in Ref.
2). Prp16p and Prp17p act before or concomitant with an
ATP-dependent step of splicing, whereas Slu7p and Prp18p act subsequent to this ATP-dependent step (6, 10-12).
After the first step of splicing, Prp16p can be efficiently
cross-linked to the 3'-splice site, and this binding is Prp17p
independent (13). After ATP hydrolysis by Prp16p, Slu7p and Prp8p can
be efficiently cross-linked to the 3'-splice site in a manner that is
dependent on Prp16p, Prp17p, and Prp18p (13). Thus the
Prp17p-dependent step is after Prp16p binds the 3'-splice
site but before or concomitant with ATP hydrolysis.
The second step of splicing is understood less in mammals. As in yeast,
there is an ATP requirement during the second step, and partially
purified second step activities have been functionally ordered with
respect to this requirement (14, 15). Recently, the mammalian
structural homologs of Prp18p (hPrp18), Prp16p (hPrp16), and Prp17p
(hPrp17) were identified (16, 17). hPrp18 and hPrp16 were both shown to
be required for the second step of splicing in vitro (16,
17). A functional role for hPrp17 has not been shown, although both
hPrp17 and hPrp16 associate with the spliceosome late in the splicing
pathway (17).
It appears that many of the second step factors are conserved between
yeast and humans. In fact, here we show that the human homolog of
Prp17p can partially complement the yeast knockout strain. The human
protein specifically increases the rate of the second step in
vitro suggesting that this protein is not only structurally
homologous to the yeast protein but also functionally related. hPrp17
localizes to the nuclear speckles in human cells, as do many splicing
factors (reviewed in Ref. 18), thus providing further support that this
protein also functions as a splicing factor in humans.
Data Base Search and cDNA Cloning--
A data base search
was performed using the Genetics Computer Group Wisconsin Sequence
Analysis Package TBLASTN program to identify human EST translations
with high homology to S. cerevisiae Prp17p.2 Alignment of two
human ESTs (AA057404 and Z19190) with the yeast sequence was the basis
for designing two oligonucleotides, 5'-GGC CGG ATC CGA CTA TCA AGG CAG
GTC CTA T-3' and 5'-GGC CGA ATT CGA CCT TAG AAG TTT CAT GAG G-3', which
were used for PCR amplification of DNA from an oligo(dT)-primed HeLa
cell cDNA library (Stratagene). The resulting 960-base pair PCR
product was gel purified and subcloned into a TA cloning vector
(Invitrogen). Both strands of the cDNA were sequenced, and the
5'-end of the cDNA was obtained using 5'-RACE-Ready cDNA
(CLONTECH) for nested PCR with the supplied anchor
primer and oligonucleotides 5'-CTG TCC TGT CTC AGT GTC CCA-3' and
5'-AAC AAT CTG ACT GCA CTG ACG CCC-3'. The 670-base pair PCR product
was purified, cloned into a TA vector, and sequenced. The 3'-end of the
cDNA was also obtained by nested PCR using a T7 primer (5'-GTA ATA
CGA CTC ACT ATA GGG C-3') specific for the library vector and
oligonucleotides 5'-AGC ATG CCA ATC AAT GGA CAA CC-3' and 5'-AGG GCC
ATA TGG TAG CAG GC-3'. The hPrp17 cDNA sequence that we obtained is
identical to that recently published by Zhou and Reed (17). Prp17p
homologs (cePrp17 cosmid Y95D11; spPrp17 GenBankTM
accession number AL021838) were aligned using PILEUP (Genetics Computer
Group) and shaded with BOXSHADE where 50% identity at a position is shaded.
In Vivo Complementation--
Full-length yPRP17, truncated
yPRP17 (amino acids 1-149), and full-length hPRP17 were cloned into
the multicopy plasmid pG1 (19) for overexpression in yeast from the
GPD1 promoter. Yeast haploid strains SJ121 (WT) and SJ136 ( In Vitro Splicing--
Whole-cell extracts were prepared as
described by Lin et al. (20) from SJ121 and SJ136 strains
that were transformed with pG1, pG1-hPRP17, or pG1-yPRP17. The actin
pre-mRNA substrate was described by O'Keefe et al. (21)
and synthesized in vitro essentially as described previously
and gel purified on an 8% denaturing acrylamide gel. Splicing
reactions were performed at 23 °C as described previously (20).
Splicing products and intermediates were visualized by autoradiography,
and the specific bands were quantified using a PhosphorImager
(Molecular Dynamics). All numbers were adjusted for molar equivalents,
and the level of second step activity was calculated as the percentage
of products (lariat product + mRNA) divided by the sum of the
intermediates and products (lariat intermediate + 5'-exon + lariat
product + mRNA).
Antibody Production and Immunofluorescence--
Rabbit
polyclonal antibodies were generated against a synthetic peptide
corresponding to amino acids 129-144 of hPrp17 (Research Genetics).
The antibodies were affinity-purified on columns with the peptide
cross-linked to CNBr-activated Sepharose beads (Amersham Pharmacia
Biotech) as described previously (22). Immunofluorescence was performed
essentially as described previously (23). HeLa cells were grown on
coverslips, fixed and stained with primary antibodies: 2 µg/ml
antigen-purified hPrp17 antibodies and 1:3000 dilution of mouse
anti-SC35 monoclonal antibody (Sigma); and secondary antibodies:
anti-rabbit IgG coupled to rhodamine and anti-mouse IgG coupled to
fluorescein. Images were photographed using an Axioskop (Carl Zeiss,
Inc.), and color photographs were processed using PHOTOSHOP software
(Adobe Systems, Mountain View, CA).
A search of GenBankTM was performed to identify a
putative human homolog of S. cerevisiae Prp17p (scPrp17p),
and PCR was used to isolate a full-length cDNA. The open reading
frame encodes a protein of 579 amino acids, and sequence alignment of
hPrp17 and yeast scPrp17p revealed an identity of 35% and similarity of 44% (Fig. 1). Probable
Schizosaccharomyces pombe (sp) and Caenorhabditis elegans (ce) homologs of Prp17p were also identified in
GenBankTM (Fig. 1). spPrp17 and cePrp17 are 41 and 51%
identical to hPrp17, respectively, and 37 and 36% identical to
scPrp17p. We also found EST sequences for portions of probable mouse,
rat, drosophila, rice, and pine Prp17 homologs (data not shown).
The highest conservation between the Prp17 proteins lies in the
carboxyl-terminal half, which contains seven WD repeats (Fig. 1). These
domains are thought to adopt a propeller-like structure, as was
previously demonstrated for the prototypical member of the WD-protein
family, To determine whether hPrp17 is functionally conserved, we used a yeast
strain in which PRP17 had been deleted (
Functional Conservation of the Human Homolog of the Yeast
Pre-mRNA Splicing Factor Prp17p*
§ and¶
**
Department of Pharmacology and Cancer
Biology, ¶ Department of Microbiology, and
Department of Medicine, Levine Science Research
Center, Duke University Medical Center, Durham, North Carolina
27710
ABSTRACT
Top
Abstract
Introduction
Procedures
Results & Discussion
References
INTRODUCTION
Top
Abstract
Introduction
Procedures
Results & Discussion
References
EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results & Discussion
References
prp17)
(kindly provided by C. Guthrie) (6) were transformed with pG1 alone,
pG1-yPRP17, pG1-yPRPC, or pG1-hPRP17, and the yeast were selected on
medium lacking tryptophan for 5 days at 25 °C. A colony was
resuspended in medium, the yeast were counted, and serial dilutions of
5-fold were made from 12,000 to 20 yeast. The yeast were grown on
medium lacking tryptophan for 3 days at 25, 30, 34, or 37 °C, and
then photographed.
RESULTS AND DISCUSSION
Top
Abstract
Introduction
Procedures
Results & Discussion
References
View larger version (81K):
[in a new window]
Fig. 1.
Putative homologs of Prp17p. Probable
human (hPrp17), C. elegans (cePrp17), and S. pombe (spPrp17) sequences were aligned with S. cerevisiae (scPrp17) using PILEUP and shaded with BOXSHADE where
50% identity at a position is shaded. The seven WD repeats are
indicated with a bar above the sequence.
-transducin (24-26). The members of the large family of WD
repeat proteins are involved in diverse functions such as signal
transduction, vesicular trafficking, cytoskeletal assembly, and cell
cycle control. Many proteins with WD repeats form multi-protein
complexes, and thus it has been proposed that these repeats promote
protein-protein interactions (27). It is interesting to note that
another yeast splicing factor, Prp4, and its mammalian homolog,
U4/U6-60 kDa protein, also contain seven WD repeats (28). Prp4
promotes the interaction between the U4/U6 and U5 snRNPs, and has been
proposed to be required for the conformational change that occurs in
the spliceosome before the first step of splicing (29). By analogy,
Prp17 may perform a similar function during the conformational change
that occurs before the second step of splicing.
prp17) (6) to
examine whether expressing the human gene could rescue the observed
temperature-sensitive phenotype. We expressed the vector alone (pG1)
full-length yeast PRP17 sequence (pG1-yPRP17), yeast PRP17, which is truncated at amino acid 149 (pG1-yPRP17C), or the full-length human sequence (pG1-hPRP17) in the
WT and prp17 strains. We compared growth of these yeast at four
different temperatures (Fig. 2 and data
not shown). As expected, the WT strain containing pG1 and the prp17
strain containing pG1-yPRP17 grow well at all the temperatures tested
(Fig. 2). However, the prp17 strain containing the vector alone or
the truncated yeast gene (pG1-yPRP17C) grows slowly at 24 and
30 °C and does not grow at higher temperatures (Fig. 2).
Significantly, the prp17 strain containing pG1-hPRP17 does grow at
24, 30, and 34 °C but not at 37 °C (Fig. 2). This indicates that
hPrp17 can partially rescue the temperature-sensitive phenotype in the
prp17 strain.
View larger version (30K):
[in a new window]
Fig. 2.
Complementation of a yeast PRP17
knockout strain. Yeast strains SJ136 ( prp17)
and SJ121 (WT) were transformed with the high copy plasmid
pG1 alone or with pG1 containing full-length yPRP17, yPRP17C (amino
acids 1-148), or hPRP17. 5-fold serial dilutions were made of the
yeast, which were then grown on medium lacking tryptophan for 3 days at
25, 30, 34, or 37 °C.
We next wanted to test whether hPrp17 could rescue the splicing defects
observed in vitro and in vivo in the prp17
strain. We made extracts from the yeast strains used above for
complementation. A time course was performed of in vitro
splicing of actin pre-mRNA with these extracts at 23 °C (Fig.
3A). The efficiency of the second step is represented as the amount of second step products (LP + mRNA) divided by the total amount of splicing intermediates and
products (LI + LP + mRNA + 5'-exon) (Fig. 3B). Extract
from the knockout strain expressing yPrp17 splices similarly to the WT
extract (Fig. 3A, lanes 1-8). Splicing with the
knockout strain containing the vector alone results in the accumulation
of splicing intermediates (LI + 5'-exon) relative to splicing products
(LP + mRNA), indicating a partial block to the second step (Fig.
3A, lanes 9-12; note that lane 12 is
underloaded on this gel). Significantly, expressing hPrp17 in the
knockout strain increases the efficiency of the second step (Fig. 3,
A, lanes 13-16 and B); therefore, hPrp17 can partially rescue the in vitro splicing defect
seen in the knockout strain, which correlates with its ability to
partially complement the temperature-sensitive phenotype in
vivo.
|
, WT with pG1; 
, 
, 
, When we looked at the in vivo splicing of RP51A and actin, the primary defect of the PRP17 knockout was the reduction of mRNA, and no preferential accumulation of unspliced precursor or lariat intermediates (data not shown). This phenotype was previously reported for the ts allele prp17-100 (30), and may result if inhibition of the second step of splicing destabilizes the splicing intermediates. Another possibility is that mutations in PRP17 or deletion of this gene affects the stability of mature RNA. Expression of yPrp17 in the knockout strain does rescue this phenotype, and expression of hPrp17 partially rescues it (data not shown). These results are again consistent with the partial complementation of the knockout strain.
To investigate the role of hPrp17 in mammalian cells, we raised antibodies to peptides corresponding to amino acids 129-144 of hPrp17. After affinity purification, these antibodies specifically detected a 65-kDa protein, the predicted molecular mass of hPrp17, on Western blots of HeLa nuclear extracts (data not shown). These antibodies were used to determine the cellular localization of hPrp17 in HeLa cells (Fig. 4). Immunostaining analysis revealed that hPrp17 is present in discrete regions in the nucleus (Fig. 4, A and B). Colocalization studies using antibodies to the splicing factor SC35 (23) (Fig. 4, C and D) revealed that these regions correspond to the nuclear speckles that are enriched in splicing components (18). hPrp17 probably does not shuttle between the nucleus and cytoplasm because both hPrp17 and SC35 remained localized to the nuclear speckles after treatment of the cells with actinomycin D (data not shown). The nuclear shuttling protein hnRNP A1 (31) was localized to the nucleus before actinomycin D treatment and had both nuclear and cytoplasmic localization after treatment (data not shown). Localization of hPrp17 in the nuclear speckles suggests that, as in yeast, hPrp17 may also function as a splicing factor in humans.
|
Together with previous complementation experiments, these results suggest that the mechanism of the second step is conserved between yeast and humans. Zhou and Reed (17) have shown that a yeast-human chimeric Prp16 protein could rescue a PRP16 knockout strain, but the full-length hPrp16 could not. Expression of hPrp18 does not rescue the yeast PRP18 knockout, but yeast Prp18p can partially complement hPrp18-depleted splicing extract in vitro (16). The yeast protein Prp22p has been shown to play a role in the second step as well as later in spliceosome disassembly (32, 33), and the human homolog of Prp22p, HRH1, can partially rescue the temperature-sensitive phenotype caused by the prp22-1 allele (34). Therefore, judging by a strict requirement of complementation of a yeast knockout strain, hPrp17 may be the most functionally conserved second step factor. The partial rescue is highly significant because the only human homolog of a splicing factor that has been reported to completely rescue a yeast knockout is the snRNP core protein D1 (35).
In summary, the results presented here provide strong evidence that hPrp17 is indeed a functional homolog of the yeast splicing factor, Prp17p. Our results, showing that hPrp17 is concentrated in nuclear speckles in HeLa cells, together with previously reported results that hPrp17 associates with purified spliceosomes (17), suggest that hPrp17 functions as a splicing factor in humans.
Acknowledgments--
We thank the Keck Foundation for support to
the Levine Science Research Center, C. Guthrie for providing the yeast
strains, J. Abelson for providing the yeast Prp17p amino acid sequence, and J. Wagner for helpful advice. We also thank the members of the
Garcia-Blanco laboratory for helpful discussions and Z.-R. Liu and E. Wagner for reviewing the manuscript.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grant R01 GM49639 (to M. A. G.-B).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AL021838.
§ Supported by the Raymond and Beverly Sackler Foundation.
** Established Investigator of the American Heart Association and a scholar of the Raymond and Beverly Sackler Foundation. To whom correspondence should be addressed. Tel.: 919-613-8632; Fax: 919-613-8646; E-mail: garci001{at}mc.duke.edu.
The abbreviations used are: snRNP(s), small ribonucleoprotein(s); EST, expressed sequence tag; PCR, polymerase chain reaction; WT, wild type; LI, lariat intermediate; LP, lariat product; WD, tryptophan and aspartic acid.
2 M. Company and J. Abelson, unpublished results.
| |
REFERENCES |
|---|
|
Top
Abstract
Introduction
Procedures
Results & Discussion
References
|
|---|
- Nilsen, T. W. (1998) in RNA Structure and Function (Simons, R. W., and Grunberg-Manago, M., eds), pp. 303-357, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
- Umen, J. G., and Guthrie, C. (1995) RNA 1, 869-885[Medline] [Order article via Infotrieve]
-
Vijayraghavan, U.,
Company, M.,
and Abelson, J.
(1989)
Genes Dev.
3,
1206-1216
[Abstract/Free Full Text] -
Vijayraghavan, U.,
and Abelson, J.
(1990)
Mol. Cell. Biol.
10,
324-332
[Abstract/Free Full Text] -
Horowitz, D. S.,
and Abelson, J.
(1993)
Mol. Cell. Biol.
13,
2959-2970
[Abstract/Free Full Text] -
Jones, M. H.,
Frank, D. N.,
and Guthrie, C.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
9687-9691
[Abstract/Free Full Text] -
Frank, D.,
Patterson, B.,
and Guthrie, C.
(1992)
Mol. Cell. Biol.
12,
5197-5205
[Abstract/Free Full Text] -
Umen, J. G.,
and Guthrie, C.
(1995)
Genes Dev.
9,
855-868
[Abstract/Free Full Text] - Umen, J. G., and Guthrie, C. (1996) Genetics 143, 723-739[Abstract]
- Schwer, B., and Guthrie, C. (1991) Nature 349, 494-499[CrossRef][Medline] [Order article via Infotrieve]
-
Horowitz, D. S.,
and Abelson, J.
(1993)
Genes Dev.
7,
320-329
[Abstract/Free Full Text] - Ansari, A., and Schwer, B. (1995) EMBO J. 14, 4001-4009[Medline] [Order article via Infotrieve]
- Umen, J. G., and Guthrie, C. (1995) RNA 1, 584-597[Abstract]
-
Sawa, H.,
Ohno, M.,
Sakamoto, H.,
and Shimura, Y.
(1988)
Nucleic Acids Res.
16,
3157-3164
[Abstract/Free Full Text] -
Lindsey, L. A.,
Crow, A. J.,
and Garcia-Blanco, M. A.
(1995)
J. Biol. Chem.
270,
13415-13421
[Abstract/Free Full Text] -
Horowitz, D. S.,
and Krainer, A. R.
(1997)
Genes Dev.
11,
139-151
[Abstract/Free Full Text] - Zhou, Z., and Reed, R. (1998) EMBO J. 17, 2095-2106[CrossRef][Medline] [Order article via Infotrieve]
- Spector, D. L. (1993) Annu. Rev. Cell Biol. 9, 265-315[CrossRef]
- Schena, M., Picard, D., and Yamamoto, K. R. (1991) in Vectors for Constitutive and Inducible Gene Expression in Yeast. Meth. Enzym. (Guthrie, C., and Fink, G. R., eds), Vol. 194, Academic Press, San Diego
-
Lin, R. J.,
Newman, A. J.,
Cheng, S. C.,
and Abelson, J.
(1985)
J. Biol. Chem.
260,
14780-14792
[Abstract/Free Full Text] - O'Keefe, R. T., Norman, C., and Newman, A. J. (1996) Cell 86, 679-689[CrossRef][Medline] [Order article via Infotrieve]
- Harlow, E., and Lane, D. (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
- Fu, X.-D., and Maniatis, T. (1990) Nature 343, 437-441[CrossRef][Medline] [Order article via Infotrieve]
- Wall, M. A., Coleman, D. E., Lee, E., Iniguez-Lluhi, J. A., Posner, B. A., Gilman, A. G., and Sprang, S. R. (1995) Cell 83, 1047-1058[CrossRef][Medline] [Order article via Infotrieve]
- Lambright, D. G., Sondek, J., Bohm, A., Skiba, N. P., Hamm, H. E., and Sigler, P. B. (1996) Nature 379, 311-319[CrossRef][Medline] [Order article via Infotrieve]
- Sondek, J., Bohm, A., Lambright, D. G., Hamm, H. E., and Sigler, P. B. (1996) Nature 379, 369-374[CrossRef][Medline] [Order article via Infotrieve]
- Neer, E. J., Schmidt, C. J., Nambudripad, R., and Smith, T. F. (1994) Nature 371, 297-300[CrossRef][Medline] [Order article via Infotrieve]
- Lauber, J., Plessel, G., Prehn, S., Will, C. L., Fabrizio, P., Groning, K., Lane, W. S., and Luhrmann, R. (1997) RNA 3, 926-941[Abstract]
- Ayadi, L., Miller, M., and Banroques, J. (1997) RNA 3, 197-209[Abstract]
-
Xu, D.,
Field, D. J.,
Tang, S.-J.,
Moris, A.,
Bobechko, B. P.,
and Friesen, J. D
(1998)
Mol. Cell. Biol.
18,
2055-2066
[Abstract/Free Full Text] - Pinol-Roma, S., and Dreyfuss, G. (1992) Nature 355, 730-732[CrossRef][Medline] [Order article via Infotrieve]
- Schwer, B., and Gross, C. (1998) EMBO J. 17, 2086-2094[CrossRef][Medline] [Order article via Infotrieve]
- Company, M., Arenas, J., and Abelson, J. (1991) Nature 349, 487-493[CrossRef][Medline] [Order article via Infotrieve]
-
Ono, Y.,
Ohno, M.,
and Shimura, Y.
(1994)
Mol. Cell. Biol.
14,
7611-7620
[Abstract/Free Full Text] -
Rymond, B. C.,
Rokeach, L. A.,
and Soch, S. O.
(1993)
Nucleic Acids Res.
21,
3501-3505
[Abstract/Free Full Text]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Cazalla, K. Newton, and J. F. Caceres A Novel SR-Related Protein Is Required for the Second Step of Pre-mRNA Splicing Mol. Cell. Biol., April 15, 2005; 25(8): 2969 - 2980. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Sapra, Y. Arava, P. Khandelia, and U. Vijayraghavan Genome-wide Analysis of Pre-mRNA Splicing: INTRON FEATURES GOVERN THE REQUIREMENT FOR THE SECOND-STEP FACTOR, Prp17 IN SACCHAROMYCES CEREVISIAE AND SCHIZOSACCHAROMYCES POMBE J. Biol. Chem., December 10, 2004; 279(50): 52437 - 52446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Chawla, A. K. Sapra, U. Surana, and U. Vijayraghavan Dependence of pre-mRNA introns on PRP17, a non-essential splicing factor: implications for efficient progression through cell cycle transitions Nucleic Acids Res., May 1, 2003; 31(9): 2333 - 2343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Shomron, H. Malca, I. Vig, and G. Ast Reversible inhibition of the second step of splicing suggests a possible role of zinc in the second step of splicing Nucleic Acids Res., October 1, 2002; 30(19): 4127 - 4137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ben-Yehuda, I. Dix, C. S. Russell, M. McGarvey, J. D. Beggs, and M. Kupiec Genetic and Physical Interactions Between Factors Involved in Both Cell Cycle Progression and Pre-mRNA Splicing in Saccharomyces cerevisiae Genetics, December 1, 2000; 156(4): 1503 - 1517. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Jiang, D. S. Horowitz, and R.-M. Xu Crystal structure of the functional domain of the splicing factor Prp18 PNAS, March 28, 2000; 97(7): 3022 - 3027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Chua and R. Reed Human step II splicing factor hSlu7 functions in restructuring the spliceosome between the catalytic steps of splicing Genes & Dev., April 1, 1999; 13(7): 841 - 850. [Abstract] [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |